抗血管内皮生长因子在眼科治疗中的趋势与挑战

Progression and challenge of anti-vascular endothelial growth factor therapy in retinal neovascular disease

眼内抗VEGF的靶向给药已经成为血管性疾病治疗领域中令人瞩目的焦点，为重塑患者视力、降低致盲率发挥了重要作用。随着对眼底血管性疾病发病机制研究及临床试验探索的不断发展和提高，抗新生血管药物的靶向治疗在诊疗策略上也在不断进行优化，而与此同时抗VEGF治疗引发的副作用也逐渐显露。本文针对抗VEGF在眼底新生血管性疾病治疗中的趋势与挑战进行分析和总结，以飨读者。

Anti-vascular endothelial growth factor （VEGF） therapy as an effective therapeutic method has been a standard treatment strategy in retinal neovascular disease, contributing to restore vision and reduce the prevalence of blindness. With the research on the pathogenesis of retinal neovaseular disease and implementation of clinical trials, anti-VEGF therapy is continuously optimized. Meanwhile, the complications after the use of anti-angiogenetic drugs are exposed. The present article summarizes the update and challenge of anti-VEGF therapy in retinal neovascular disease.